ABOUT PREMIER RESEARCH

We’re built for biotech

We recognize that when an emerging biotech is built around a single asset, focus and flexibility are critical to success. 

And, since many of our customers require additional infrastructure, we fill in resourcing gaps to help their product reach the patient faster. We are a full-service CRO and offer strategies that are customized for each program, with tailored processes designed to meet highly specific needs. 

Firsthand experience with many different systems and processes informs our decisions on what will work best for individual customers. We complement our customers’ team with specialized expertise in your therapeutic area and reduce the burden of analysis with a proprietary analytical platform to discover insights faster. 

Premier Research leverages leading technologies and predictive recruitment models, so that our teams can build statistical, adaptive approaches and find efficiencies that support Fast Track designation and orphan drug status. 

We’ve created a specialized global team dedicated to protocol development and accelerating investigator site selection for study startup. Our regulatory consultants are available throughout development from phase I through post-marketing to support trial design, regulatory submissions, and compliance.

We are adaptable, passionate, and customer-focused — smart, experienced, and united by a desire to help change the course of medical science. We’re constantly building on our past successes to have direct impact on the outcome of our customers’ development plans. If you’re looking for a clinical development partner that delivers outcome-focused insight and shares your commitment to developing life-changing therapies, we should talk.
 

FEATURED PRODUCTS

End-To-End Oncology Development End-To-End Oncology Development

Pioneers developing the latest targeted therapies turn here for innovation and expertise. We’ve conducted over 155 trials across numerous indications in the past five years.

CONTACT INFORMATION

Premier Research

One Park Drive

Durham, NC 27709

UNITED STATES

Phone: + 1 910 447 3156

Contact: Karen Brown

FEATURED ARTICLES

  • Premier Research Champions Patient Advocacy Community

    As part of its commitment to supporting the patient advocacy community and as a kickoff to Rare Disease Day on February 28 and March as Rare Disease Month, clinical research company Premier Research is announcing both a new scholarship for rare disease patient advocates in partnership with Professional Patient Advocates in Life Sciences (PPALS) and the launch of a new Patient and Stakeholder Engagement (PASE) capability led by Juliet Moritz.

  • The Placebo Problem In Pain Research Keeping Up With The ‘Mrs Joneses’
    The Placebo Problem In Pain Research Keeping Up With The ‘Mrs Joneses’

    Pain trials are uniquely challenging because they rely so heavily on patients’ own assessments. While researchers will always need to account for the placebo effect when studying indications as subjective as neuropathic pain, there are ways to increase the likelihood of achieving objective trial outcomes.

  • It’s About How The Social System Works, Not Just The Science
    It’s About How The Social System Works, Not Just The Science

    After a failed attempt from their first CRO, this manufacturer turned to Premier Research to successfully recruit and retain 24 patients for a Phase I proof-of-concept study of inflammatory bowel disease.

  • A Strategic Partner, Or A Vendor Looking To You For The Answers?
    A Strategic Partner, Or A Vendor Looking To You For The Answers?

    Any capable CRO can provide manpower and execute orders on behalf of a sponsor, no questions asked, with little stake or interest in the endeavor’s ultimate success. What you need is a strategic ally, a company that joins you, lockstep, in pursuing shared goals and greater outcomes. Not a vendor, but a partner.

  • 6 Early Phase Dose-Finding Trial Designs For Oncology Therapeutics
    6 Early Phase Dose-Finding Trial Designs For Oncology Therapeutics

    The optimal dose-finding strategy for a given therapeutic agent and indication is based on a multitude of factors, accentuating the need for individual tailoring in oncology drug trial design. Read on for a look at six of the most common dose-finding trial designs in oncology today.

  • Ethical Considerations In Adaptive Design Clinical Trials
    Ethical Considerations In Adaptive Design Clinical Trials

    While adaptive design is associated with many potential benefits, it may also present challenges to observing the basic ethical principles of research in human subjects. In this white paper, we review the features of particular clinical trial design adaptations and discuss the ethical obstacles they can present and those they can potentially resolve. Using examples of both published and unpublished clinical studies, we highlight the importance of proper design and planning and appropriate ethical due diligence in the successful conduct of an adaptive design clinical trial.

  • 5 Must-Dos To Build Trust Between An Early-Stage Biotech And CRO

    Take these steps to create a trusted partnership with your CRO and achieving a much more accurate and financially workable CRO agreement.

  • CAR-T Cell Therapies: Safety Considerations and Toxicity Management
    CAR-T Cell Therapies: Safety Considerations and Toxicity Management

    Along with demonstrated efficacy in hematologic malignancies, CAR-T cells have the capacity to elicit serious toxicities. Safety considerations related to CAR-T cells may impact both trial design and trial management, as the adverse events (AEs) associated with immuno-oncology agents differ from those associated with cytotoxic therapies. Learn how to make anticipating, preventing and managing toxicity a key component of clinical studies involving CAR-T cells.

  • 4 Potential Advantages Of Adaptive Design
    4 Potential Advantages Of Adaptive Design

    Adaptive design strategies have been especially useful for rare disease research in general and rare oncology in particular. Read more to see how the savvy application of adaptive trial design compares to conventional study designs.

  • 5 Endpoints For Rare Oncology Trials
    5 Endpoints For Rare Oncology Trials

    For patients battling rare cancers, especially those lacking standard treatments, they don’t have the time to wait for more concrete measures. In these cases, choosing the appropriate endpoint for a trial is crucial. Read on for a rundown of the five major types of clinical endpoints in rare oncology and the best way to use them.

  • From Laboratory To Bedside: Expediting Development Of Novel Rare Cancer Treatments
    From Laboratory To Bedside: Expediting Development Of Novel Rare Cancer Treatments

    This webinar shares new insights on rare oncology drug development and examines how new processes and regulatory pathways are helping speed development of novel therapies.

  • Driving Product Development And Finding The Fast Track In Early-Phase Oncology Programs
    Driving Product Development And Finding The Fast Track In Early-Phase Oncology Programs

    This webinar highlights the many aspects a company must consider in planning and executing a trial, and how a CRO can help throughout the process.

  • Immuno-Gene Therapeutics In Hematological Cancers: How Science Drives Study Strategy
    Immuno-Gene Therapeutics In Hematological Cancers: How Science Drives Study Strategy

    This webinar reviews the current state of technology in gene therapeutics and examines trends in immuno-oncology and gene therapy for hematological malignancies.

  • The Complex Issues With Developing A Novel Human Antibody From Scratch
    The Complex Issues With Developing A Novel Human Antibody From Scratch

    Having the right specialists on their team enables Premier Research to recruit subjects relatively quickly, despite extremely complex selection criteria for this multiple myeloma clinical trial. In addition, maintaining a close and cooperative customer relationship assisted in moving the study forward.

  • Overcoming The Challenge Of Enrolling Sickle Cell Patients In Clinical Trials
    Overcoming The Challenge Of Enrolling Sickle Cell Patients In Clinical Trials

    Premier Research was given a tight timeline of less than four months from delivery of the final protocol to first patient in. With proper site selection to accommodate the needs of a fast start-up along with open and frequent communication with the principle investigator and the project team, they were able to meet this timeline.

  • Recruiting Hard-To-Find Patients From A Specific HLA Subgroup
    Recruiting Hard-To-Find Patients From A Specific HLA Subgroup

    CRO helps company overcome early patient screening failure rate of 70 percent as well as assisting with instituting new protocols and renegotiating contracts as the study experiences and major change of direction.

  • Lengthy Cancer Drug Study Using Dozens Of Sites Yields Positive Results
    Lengthy Cancer Drug Study Using Dozens Of Sites Yields Positive Results

    After lengthy recruiting process and a five year long clinical trial spread across more than two dozen sites, sponsor calls study results “an unexpectedly huge step forward” in overcoming the limited efficacy of current treatments and continues partnership with CRO.

  • CRO Helps To Identify A Highly Productive Location For Siting Future Studies
    CRO Helps To Identify A Highly Productive Location For Siting Future Studies

    Failure to transmit data collected effectively stalled a clinical trial study of an inflammation control drug. With help from a CRO, important lessons were learned about need for discipline and following protocol as well as the identification of Russia as a highly desirable site for clinical trials.

  • Five Things To Know When it Comes To iRECIST
    Five Things To Know When it Comes To iRECIST

    Here are five things you should know about iRECIST as the standard shapes up as an important tool in assessing solid tumors.

  • Maximizing Success In Early Stage Oncology Trials: Considerations And Strategies In The Era Of Molecularly Targeted Agents
    Maximizing Success In Early Stage Oncology Trials: Considerations And Strategies In The Era Of Molecularly Targeted Agents

    Making a meaningful impact on the survival and quality of life of patients with cancer remains a significant challenge. This white paper discusses considerations and strategies for maximizing the likelihood of success in early phase oncology trials and developing significantly improved therapeutics for patients.